Last reviewed · How we verify
Nitroprusside, Sodium — Competitive Intelligence Brief
marketed
Nitrovasodilator
Soluble guanylate cyclase (via nitric oxide)
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Nitroprusside, Sodium (Nitroprusside, Sodium) — Cristália Produtos Químicos Farmacêuticos Ltda.. Sodium nitroprusside releases nitric oxide, which activates guanylate cyclase to increase cGMP levels, causing vasodilation of both arteries and veins.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Nitroprusside, Sodium TARGET | Nitroprusside, Sodium | Cristália Produtos Químicos Farmacêuticos Ltda. | marketed | Nitrovasodilator | Soluble guanylate cyclase (via nitric oxide) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Nitrovasodilator class)
- Cristália Produtos Químicos Farmacêuticos Ltda. · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Nitroprusside, Sodium CI watch — RSS
- Nitroprusside, Sodium CI watch — Atom
- Nitroprusside, Sodium CI watch — JSON
- Nitroprusside, Sodium alone — RSS
- Whole Nitrovasodilator class — RSS
Cite this brief
Drug Landscape (2026). Nitroprusside, Sodium — Competitive Intelligence Brief. https://druglandscape.com/ci/nitroprusside-sodium. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab